Kabra Drugs Ltd Stock Price Today (NSE: KABRADG)
Fundamental Score
Kabra Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kabra Drugs Ltd share price today is ₹18.61, up +0.38% on NSE/BSE as of 22 September 2026. Kabra Drugs Ltd (KABRADG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹44.12 (Cr). The 52-week high for KABRADG share price is ₹35.52 and the 52-week low is ₹15.50. At a P/E ratio of 5.82x, KABRADG is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.28% and a debt-to-equity ratio of 0.02.
Kabra Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Kabra Drugs Ltd share price chart: 6.36% return over the past month. 52-week high ₹35.52, 52-week low ₹15.50.
Kabra Drugs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹19.54 | ₹19.54 | ₹18.00 | ₹18.54 | 59.70K (Cr) | |
| ₹19.25 | ₹19.83 | ₹18.80 | ₹19.08 | 58.83K (Cr) | |
| ₹19.77 | ₹19.77 | ₹18.90 | ₹19.22 | 64.19K (Cr) | |
| ₹19.46 | ₹19.94 | ₹18.53 | ₹19.05 | 14.91K (Cr) | |
| ₹20.30 | ₹20.89 | ₹19.40 | ₹19.46 | 81.90K (Cr) | |
| ₹20.14 | ₹21.25 | ₹19.30 | ₹20.65 | 64.23K (Cr) | |
| ₹21.21 | ₹21.24 | ₹19.85 | ₹20.14 | 61.17K (Cr) | |
| ₹21.00 | ₹21.50 | ₹20.00 | ₹20.90 | 87.04K (Cr) | |
| ₹20.06 | ₹21.98 | ₹19.91 | ₹20.69 | 91.14K (Cr) | |
| ₹20.95 | ₹20.95 | ₹19.98 | ₹20.18 | 33.65K (Cr) |
Kabra Drugs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹19.70 | ₹21.98 | ₹18.00 | ₹18.54 | -5.89% | |
| ₹23.61 | ₹24.27 | ₹22.50 | ₹22.93 | -2.88% | |
| ₹25.90 | ₹28.35 | ₹20.10 | ₹22.99 | -11.24% | |
| ₹26.03 | ₹28.18 | ₹23.16 | ₹24.40 | -6.26% | |
| ₹24.58 | ₹29.45 | ₹23.30 | ₹26.03 | +5.90% | |
| ₹29.15 | ₹32.07 | ₹24.50 | ₹24.58 | -15.68% | |
| ₹28.90 | ₹35.52 | ₹27.64 | ₹30.52 | +5.61% | |
| ₹31.27 | ₹33.00 | ₹25.64 | ₹28.62 | -8.47% | |
| ₹32.64 | ₹32.66 | ₹25.46 | ₹30.55 | -6.40% | |
| ₹19.37 | ₹31.15 | ₹18.50 | ₹31.11 | +60.61% | |
| ₹17.85 | ₹20.49 | ₹15.50 | ₹18.92 | +5.99% | |
| ₹20.35 | ₹20.35 | ₹17.08 | ₹17.69 | -13.07% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kabra Drugs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kabra Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KABRADG across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (18.28%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.15%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 5.82 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (524.17%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (546.43%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (48.00% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (96.85% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (191.69x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 43.84)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-15.62 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kabra Drugs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kabra Drugs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Kabra Drugs LtdKabra Drugs Ltd...Selected✓ KABRADG • 524322 | 50.2/100 | ₹18.61₹19 | ₹44.12₹44.12 | 5.82Average 5.8 Average | 18.28%Good 18.28% Good | 21.15%Excellent 21.15% Excellent | 0.02Excellent 0.0 Excellent | 96.85%Excellent 96.85% Excellent | — — | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Kabra Drugs Ltd Quarterly Performance
Latest quarterly metrics for KABRADG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
546.43%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
524.17%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
96.85%
Compounded annual net profit growth over 5 years
Kabra Drugs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KABRADG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Kabra Drugs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Kabra Drugs Ltd (KABRADG) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Kabra Drugs Ltd
About KABRADG (Kabra Drugs Ltd)
Kabra Drugs Ltd is a dormant entity in the pharmaceutical sector, currently holding no active operational functions. Historically, Kabra Drugs Ltd participated in the manufacturing... and commercial exchange of pharmaceutical related goods, though these activities have ceased. The company's original ambition focused on permaculture, a sustainable agricultural system, hinting at an earlier diversification strategy into eco-friendly practices. This suggests a potential for incorporating environmentally conscious manufacturing processes should the company choose to reactivate. Established in 1989, Kabra Drugs Ltd has maintained its headquarters in Chennai, India, as its registered base. While currently inactive, the company's registration as a pharmaceutical entity provides a potential framework for future development within the industry. The existing infrastructure and knowledge base, however outdated, could offer a foundation for re-entry into the market, either through internal restructuring or external collaborations. The company's long-standing presence, even in dormancy, suggests a level of legacy and brand awareness that could be leveraged in any future endeavors. The current state of Kabra Drugs Ltd necessitates a significant reevaluation of its business model and strategic direction should it seek to revitalize its operations. Market analysis, investment in updated technology, and a renewed focus on regulatory compliance would be essential to compete effectively in the modern pharmaceutical landscape. The shift from active engagement to dormancy represents a turning point in the company's history, demanding bold leadership and innovative strategies to navigate the challenges and opportunities that lie ahead.
Company Details
Key Leadership
KABRADG Share Price: Frequently Asked Questions
What is the current share price of Kabra Drugs Ltd?
Kabra Drugs Ltd (KABRADG) trades at ₹18.61 on NSE and BSE. Market cap ₹44.12 (Cr). Educational data only.
What is the P/E ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd has a P/E of 5.82x vs industry average 34.89x.
What is the Bull Run score for Kabra Drugs Ltd?
Kabra Drugs Ltd has a Bull Run score of 50.2/100 based on 25+ financial parameters.
Does Kabra Drugs Ltd pay dividends?
Kabra Drugs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Kabra Drugs Ltd?
Kabra Drugs Ltd has ROE of 18.28%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd has debt-to-equity of 0.02.
Is Kabra Drugs Ltd a good investment?
Bull Run gives Kabra Drugs Ltd a score of 50.2/100. This is not investment advice — consult a SEBI-registered advisor.